Literature DB >> 25195113

[Stereotactic body radiation therapy in the management of liver tumours].

J Jacob1, F Nguyen2, E Deutsch2, F Mornex3.   

Abstract

Stereotactic radiotherapy is a high-precision technique based on the administration of high doses to a limited target volume. This treatment constitutes a therapeutic progress in the management of many tumours, especially hepatic ones. If surgery remains the standard local therapy, stereotactic radiotherapy is first dedicated to inoperable patients or unresectable tumours. Patients with moderately altered general status, preserved liver function and tumour lesions limited in number as in size are eligible to this technique. Results in terms of local control are satisfying, regarding primary tumours (notably hepatocellular carcinomas) as metastases stemming from various origins. If treatment protocols and follow-up modalities are not standardized to this day, iconographic acquisition using four-dimensional computed tomography, target volumes delineation based on morphological and/or metabolic data, and image-guided radiotherapy contribute to an oncologic efficacy and an improved sparing of the functional liver. The purpose of this literature review is to report the results of the main works having assessed stereotactic radiotherapy in the management of primary and secondary liver tumours. Technical particularities of this radiation modality will also be described.
Copyright © 2014 Société française de radiothérapie oncologique (SFRO). Published by Elsevier SAS. All rights reserved.

Entities:  

Keywords:  Foie; Liver; Metastases; Métastases; Primary tumours; Radiothérapie stéréotaxique; Stereotactic radiotherapy; Tumeurs primitives

Mesh:

Year:  2014        PMID: 25195113     DOI: 10.1016/j.canrad.2014.07.145

Source DB:  PubMed          Journal:  Cancer Radiother        ISSN: 1278-3218            Impact factor:   1.018


  1 in total

Review 1.  Management of liver cancer. The Surgeon's point of view.

Authors:  Pierre Rabinel; Damien Dousse; Fabrice Muscari; Bertrand Suc
Journal:  Rep Pract Oncol Radiother       Date:  2017-03-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.